Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 May 12:7:51.
doi: 10.12703/P7-51. eCollection 2015.

Recent advances in renal transplantation: antibody-mediated rejection takes center stage

Eric Pouliquen #  1   2   3 , Alice Koenig #  1   2   3 , Chien Chia Chen  1   2   3 , Antoine Sicard  1   2   3 , Maud Rabeyrin  4 , Emmanuel Morelon  1   2   3 , Valérie Dubois  5 , Olivier Thaunat  1   2   3
Affiliations
Review

Recent advances in renal transplantation: antibody-mediated rejection takes center stage

Eric Pouliquen et al. F1000Prime Rep. .

Abstract

Overlooked for decades, antibodies have taken center stage in renal transplantation and are now widely recognized as the first cause of allograft failure. Diagnosis of antibody-mediated rejection has considerably improved with identification of antibody-mediated lesions in graft biopsies and advances made in the detection of circulating donor-specific antibodies. Unfortunately, this progress has not yet translated into better outcomes for patients. Indeed, in the absence of a drug able to suppress antibody generation by plasma cells, available therapies can only slow down graft destruction. This review provides an overview of the current knowledge of antibody-mediated rejection and discusses future interesting research directions.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Schematic representation of antibody-mediated rejection pathophysiology
Mechanisms of action of therapies are indicated. Therapies currently used are in bold red; drugs under evaluation are in dashed orange. AMR, antibody-mediated rejection; Conv, convertase; IV, intravenous; MAC, membrane attack complex; MHC, major histocompatibility complex; mTOR, mammalian target of rapamycin; NK, natural killer.
See this image and copyright information in PMC

References

    1. Schieppati A, Remuzzi G. Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney international. Supplement. 2005:S7–S10. doi: 10.1111/j.1523-1755.2005.09801.x. - DOI - PubMed
    1. Gorer PA. The antigenic basis of tumour transplantation. J Pathol. 1938;47:231–52. doi: 10.1002/path.1700470204. - DOI
    1. Billingham RE, Medawar PB. The Technique of Free Skin Grafting in Mammals. Journal of Experimental Biology. 1951;28:385–402.
    1. Benichou G, Yamada Y, Yun S, Lin C, Fray M, Tocco G. Immune recognition and rejection of allogeneic skin grafts. Immunotherapy. 2011;3:757–70. doi: 10.2217/imt.11.2. - DOI - PMC - PubMed
    1. Sellarés J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, Hidalgo LG, Famulski K, Matas A, Halloran PF. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2012;12:388–99. doi: 10.1111/j.1600-6143.2011.03840.x. - DOI - PubMed

    2. http://f1000.com/prime/720796354